- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Response to Sipuleucel-T in Prostate Cancer
Authors
Keywords
-
Journal
Cancers
Volume 4, Issue 2, Pages 420-441
Publisher
MDPI AG
Online
2012-04-18
DOI
10.3390/cancers4020420
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)
- (2017) T. M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer.
- (2017) F. P. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T.
- (2017) N. A. Sheikh et al. JOURNAL OF CLINICAL ONCOLOGY
- Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials.
- (2017) E. J. Small et al. JOURNAL OF CLINICAL ONCOLOGY
- Sipuleucel-T product characterization across different disease states of prostate cancer.
- (2017) Nadeem A. Sheikh et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term Cancer Risk among People Diagnosed with AIDS during Childhood
- (2012) E. P. Simard et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Immunotherapy eradicates metastases with reversible defects in MHC class I expression
- (2011) Cristina Garrido et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Metastasis: Molecular Insights and Evolving Paradigms
- (2011) Scott Valastyan et al. CELL
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- (2011) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
- (2011) T. M. Beer et al. CLINICAL CANCER RESEARCH
- Ipilimumab
- (2011) Fiona Cameron et al. DRUGS
- TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development
- (2011) Dae Won Kim et al. Human vaccines & immunotherapeutics
- Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer
- (2011) Simon J. Hall et al. JOURNAL OF UROLOGY
- Cancer Immunotherapy: Sipuleucel-T and Beyond
- (2011) Aimee E Hammerstrom et al. PHARMACOTHERAPY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses
- (2010) Matthew D. Morse et al. HUMAN IMMUNOLOGY
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force
- (2010) Lisa H Butterfield et al. Journal of Translational Medicine
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
- (2010) R. A. Madan et al. ONCOLOGIST
- Immune cell infiltration of primary and metastatic lesions: Mechanisms and clinical impact
- (2010) James E. Talmadge SEMINARS IN CANCER BIOLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
- (2009) Kathleen Ebelt et al. EUROPEAN JOURNAL OF CANCER
- Mechanisms of T-cell inhibition: implications for cancer immunotherapy
- (2009) Elizabeth A Mittendorf et al. Expert Review of Vaccines
- The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
- (2008) A. Curti et al. BLOOD
- Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
- (2008) Celestia S. Higano et al. CANCER
- Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations
- (2008) Natalia Aptsiauri et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD54 is a surrogate marker of antigen presenting cell activation
- (2008) N. A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement
- (2008) C. T. Garnett et al. CLINICAL CANCER RESEARCH
- Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
- (2008) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started